Trial reportJournal of pediatric and adolescent gynecology2018
Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.
Trial report in Journal of pediatric and adolescent gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- A Validated Model for Individualized Prediction of Live Birth in Patients With Adenomyosis Undergoing Frozen-Thawed Embryo Transfer.Frontiers in endocrinology · 2022Trial
- Perceived cognitive functioning difficulties in individuals living with endometriosis.Journal of health psychology · 2025Article
- Anti-Angiogenic RNAi-Based Treatment of Endometriosis in a Rat Model Using CXCR4-Targeted Peptide Nanoparticles.International journal of molecular sciences · 2025Article
- Review
- Article
- Nanonization and Deformable Behavior of Fattigated Peptide Drug in Mucoadhesive Buccal Films.Pharmaceutics · 2024Article
- Pain mechanisms in the transgender individual: a review.Frontiers in pain research (Lausanne, Switzerland) · 2024Review
- Considerations for hormonal therapy in migraine patients: a critical review of current practice.Expert review of neurotherapeutics · 2023Review
- Association Between Uterine Volume and In Vitro Fertilization (IVF) Reproductive Outcomes of Infertile Patients with Adenomyosis.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- The Sphingosine 1-Phosphate Axis: an Emerging Therapeutic Opportunity for Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- GnRH agonists in the treatment of symptomatic endometriosis: a review.F&S reports · 2023Article
- A supportive text message intervention for individuals living with endometriosis (EndoSMS): Randomized controlled pilot and feasibility trial.Contemporary clinical trials communications · 2023Article
- Total Flavonoids of Polygala fallax Hemsl Induce Apoptosis of Human Ectopic Endometrial Stromal Cells through PI3K/AKT/Bcl-2 Signaling Pathway.Gynecologic and obstetric investigation · 2023Article
- Pubertal Blockade and Subsequent Gender-Affirming Therapy.JAMA network open · 2022Article
- Integrated bioinformatic analysis of dysregulated microRNA-mRNA co-expression network in ovarian endometriosis.Acta obstetricia et gynecologica Scandinavica · 2022Article
- Reproductive and postsurgical outcomes of infertile women with deep infiltrating endometriosis.BMC women's health · 2022Article
- Hydroxyl Group-Targeted Conjugate and Its Self-Assembled Nanoparticle of Peptide Drug: Effect of Degree of Saturation of Fatty Acids and Modification of Physicochemical Properties.International journal of nanomedicine · 2022Article
- Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis.Frontiers in global women's health · 2022Review
- Current Challenges in the Management of Chronic Pelvic Pain in Women: From Bench to Bedside.International journal of women's health · 2022Review
- Melatonin protects against ovarian damage by inhibiting autophagy in granulosa cells in rats.Clinics (Sao Paulo, Brazil) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
STUDY
objectiveTo explore the potential occurrence of long-term side effects and tolerability of gonadotropin-releasing hormone agonist (GnRHa) plus 2 different add-back regimens in adolescent patients with endometriosis.
designFollow-up questionnaire sent in 2016 to patients who participated in a drug trial between 2008 and 2012.
settingTertiary care center in Boston, Massachusetts.
participantsFemale adolescents with surgically confirmed endometriosis (n = 51) who enrolled in a GnRHa plus add-back trial as adolescents.
interventionsLeuprolide depot 11.25 mg intramuscular injection every 3 months, plus oral norethindrone acetate 5 mg daily or oral norethindrone acetate 5 mg daily and oral conjugated equine estrogens 0.625 mg daily.
main outcome measuresSide effects during and after treatment, irreversible side effects, changes in pain, overall satisfaction.
resultsThe response rate was 61% (25 of 41; 10 subjects could not be located). Almost all (24 of 25) reported side effects during treatment; 80% (16 of 21) reported side effects lasting longer than 6 months after stopping treatment. Almost half (9 of 20) reported side effects they considered irreversible, including memory loss, insomnia, and hot flashes. Despite side effects, participants rated GnRHa plus add-back as the most effective hormonal medication for treating endometriosis pain; two-thirds (16 of 25) would recommend it to others. More participants who received a modified 2-drug add-back regimen vs standard 1-drug add-back would recommend GnRHa and believed it was the most effective hormonal medication.
conclusionSubjects believed that GnRHa used with add-back was effective and would recommend it to others, despite significant side effects. Those who received 2-drug add-back reported more success than those who received standard add-back. A subset of patients reported side effects they consider to be irreversible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.